CTNNB1

Across TCGA pan-cancer cohorts, CTNNB1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CTNNB1 data layer compared with 23 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CTNNB1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CTNNB1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where CTNNB1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.627	0.435	.004	16	view →
CCRCC	OS	Quartile	All	1.000	0.476	.028	9	view →
LUAD	DFS	Median	II,III,IV	0.718	0.940	.007	4	view →
HNSC	OS	Quartile	IV	0.751	1.000	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CTNNB1–PDAC (OS)

Open the PDAC breakdown →